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licenses/by-nc-nd/4.0/).Rationale & Objective: Previous studies of
inflammation and anemia management in hemodi-
alysis (HD) patients may be biased due to patient
differences. We used a self-matched longitudinal
design to test whether new inflammation, defined
as an acute increase in C-reactive protein (CRP)
level, reduces hemoglobin response to
erythropoiesis-stimulating agent (ESA) treatment.
Study Design: Self-matched longitudinal design.
Setting & Participants: 3,568 new inflammation
events, defined as CRP level > 10 mg/L following a
3-month period with CRP level ≤ 5 mg/L, were
identified from 12,389 HD patients in the Dialysis
Outcomes and Practice Patterns Study (DOPPS)
phases 4 to 6 (2009-2018) in 10 countries in
which CRP is routinely measured.
Predictor: “After” (vs “before”) observing a high
CRP level.
Outcomes: Within-patient changes in hemoglobin
level, ESA dose, and ESA hyporesponsiveness
(hemoglobin < 10 g/dL and ESA dose > 6,000
[Japan] or >8,000 [Europe] U/wk).
Analytical Approach: Linear mixed models and
modified Poisson regression.Editorial, p 245
286Results: Comparing before with after periods,
mean hemoglobin level decreased from 11.2 to
10.9 g/dL (adjusted mean change, −0.26 g/dL),
while mean ESA dose increased from 6,320 to
6,960 U/wk (adjusted relative change, 8.4%). The
prevalence of ESA hyporesponsiveness increased
from 7.6% to 12.3%. Both the unadjusted and
adjusted prevalence ratios of ESA hypores-
ponsiveness were 1.68 (95% CI, 1.48-1.91).
These associations were consistent in sensitivity
analyses varying CRP thresholds and were stron-
ger when the CRP level increase was sustained
over the 3-month after period.
Limitations: Residual confounding by unmeasured
time-varying risk factors for ESA
hyporesponsiveness.
Conclusions: In the 3 months after HD patients
experienced an increase in CRP levels, hemoglo-
bin levels declined quickly, ESA doses increased,
and the prevalence of ESA hyporesponsiveness
increased appreciably. Routine CRP measurement
could identify inflammation as a cause of worsened
anemia. In turn, these findings speak to a poten-
tially important role for anemia therapies that are
less susceptible to the effects of inflammation.Best practice guidelines for anemia management inhemodialysis (HD) patients, including use of
erythropoiesis-stimulating agents (ESAs), have varied over
time and by international region, with a lower hemoglo-
bin level threshold of 10 g/dL frequently targeted.1-6Randomized trials have demonstrated the cardiovascular
harm of targeting higher hemoglobin levels in anemic
patients with chronic kidney disease,7-10 but the mecha-
nism remains unclear. ESA hyporesponse has been associ-
ated with worse survival, and this association is driven at
least in part by poor outcomes in patients who require the
highest doses.11 The US Food and Drug Administration has
recommended to use the lowest ESA dose needed to avoid
transfusions in patients who have not demonstrated suffi-
cient response to ESA therapy.12 Financial incentives and
clinical risk mitigation strategies to reduce ESA doses alsomotivate the need to distinguish between HD patients who
may require higher ESA doses to achieve hemoglobin
levels ≥ 10 g/dL and those who may be overtreated. ESA
hyporesponsiveness is thought to be present in w10% of
HD patients13,14 and is commonly defined as one of the
following: (1) a decrease in hemoglobin level at constant
ESA dose, (2) an increase in ESA dose to preserve a similar
hemoglobin level, or (3) a failure to increase hemoglobin
level into the target range despite large ESA doses.2
Inflammation, easily identified clinically by a high C-
reactive protein (CRP) level, is common in HD patients
and associated with increased mortality.15-18 Inflamma-
tion may also blunt the hematopoietic response of ESA
therapy to produce hemoglobin by decreasing bone
marrow response to ESAs, altering iron regulation
through hepcidin, and/or causing hemolysis of red
blood cells/erythrocytes.13,16,19,20 Several cross-sectional
analyses have shown a positive correlation between
CRP level and ESA dose.21-25 However, longitudinalKidney Med Vol 2 | Iss 3 | May/June 2020
Figure 1. Illustration of before-after study design. For a given patient, average hemoglobin (Hgb) level and erythropoiesis-stimulating
agent (ESA) dose were observed during the 3 months following an increase in C-reactive protein (CRP) level from low (≤5 mg/L) to
high (>10 mg/L). Time-varying confounders were included during the month preceding the “before” period (C1) and the month pre-
ceding the CRP level increase (C2).
Original Researchstudies have been less frequent and have used a variety
of analytic approaches.26-28
In this study, we focus on newly developed inflam-
mation and aim to quantify the magnitude of within-
patient changes in hemoglobin levels and ESA doses
relative to preinflammation levels. We hypothesized that
patients are more likely to be ESA hyporesponsive, with
lower hemoglobin levels and/or larger ESA doses in the 3
months after an increase in CRP level (from ≤5 to >10
mg/L) compared with the 3 months before this increase.
METHODS
Data Source
The Dialysis Outcomes and Practice Patterns Study
(DOPPS) is an international multiphase prospective cohort
study of patients 18 years and older treated with in-center
HD in 21 countries. Maintenance HD patients were
randomly selected from national samples of HD facilities in
each country; detailed information is included in prior
publications29,30 and at http://www.dopps.org. Study
approval and patient consent were obtained as required by
national and local ethics committee regulations. Informa-
tion for patient demographics and comorbid condition
history was abstracted from medical records at DOPPS
enrollment in each phase. Monthly data for measured
laboratory values and medication prescriptions were
abstracted from medical records at baseline and during
follow-up.
This analysis included HD patients from 10 DOPPS
countries for which monthly CRP data were widely avail-
able: Japan, Australia and New Zealand (ANZ), and 7
countries in Europe: Belgium, France, Germany, Italy,
Spain, Sweden, and the United Kingdom. No data from the
United States or Canada were used because routine mea-
surement of CRP in the HD setting remains rare in North
America.31 Countries were included only during phases
when data for laboratory values and medications were
collectedmonthly: all 10 countries in DOPPS phase 4 (2009-
2011), all countries except Belgium and Sweden in phase 5
(2012-2015), and only Japan in phase 6 (2015-2018).Kidney Med Vol 2 | Iss 3 | May/June 2020Study Design
Our goal was to assess whether newly developed inflam-
mation led to increased ESA resistance. To operationalize
this hypothesis, we considered CRP level to be a surrogate
for inflammation and used a self-matched before-after
study design as illustrated in Figure 1 to assess within-
patient changes in hemoglobin levels, ESA doses, and
ESA hyporesponsiveness from the “before” period (little or
no inflammation) to the “after” period (following the
onset of inflammation). This self-matched design prevents
confounding due to fixed patient characteristics, for
example, sex, baseline age, and comorbid condition his-
tory, as well as other unmeasured confounders such as
genetic or environmental factors.
Because longitudinal ascertainment of CRP level was
required, we excluded patients with fewer than 2 CRP
measurements during DOPPS follow-up and facilities that
did not routinely assess CRP, defined as CRP data available
in >25% of patient-months (ie, measured at least once
every 4 months on average). The remaining patients were
potentially eligible for inclusion. We then identified in-
stances of high CRP levels (>10 mg/L), considered
“month 0.” These instances needed to meet 4 additional
criteria to be included in the matched analysis: (1) the
patient was enrolled in DOPPS for 4 or more months
before month 0, (2) CRP was measured at least once
during the 3 months before month 0, (3) all available CRP
values were low (≤5 mg/L) during the 3 months before
month 0, and (4) the patient remained in DOPPS for 3 or
more months following month 0. Detailed information on
the number excluded for various reasons is shown in the
flow diagram (Fig 2).
Statistical Analyses
We first summarized the distribution of CRP levels by
country. After applying the inclusion/exclusion criteria
above, we summarized both time-fixed and time-varying
patient characteristics of the study sample used in the
matched analysis. In descriptive analyses to illustrate trends
in hemoglobin level, ESA dose, and ESA hyporesponsive-
ness over the 3 months before and after the CRP increase,287
Figure 2. Flow chart illustrates inclusion/exclusion criteria. *Routine measurement of C-reactive protein (CRP) by a facility defined
as ≥25% of patient-months with a CRP measurement, that is, CRP measured at least once every 4 months on average. Note that the
194,917 CRP measurements from 12,389 patients were used as the basis to report the distribution of CRP in Figure 3. Abbrevi-
ation: DOPPS, Dialysis Outcomes and Practice Patterns Study.
Original Researchthe mean and 95% confidence interval (CI) were calculated
in each month. To convert ESA doses to units of intrave-
nous (IV) epoetin, we used conversion factors of 250:1 for
darbepoetin,32 208:1 (250/1.2) for pegylated epoetin
beta,33 and 1.15:1 for subcutaneous injections.34
ESA hyporesponsiveness, the main binary outcome, was
defined in each 3-month period as low hemoglobin level
(<10 g/dL) plus high ESA dose, for which the threshold
for high ESA dose was lower in Japan (>6,000 U/wk) than
in Europe/ANZ (>8,000 U/wk) due to generally lower
ESA doses in Japan. Hemoglobin levels and ESA doses were
averaged over each 3-month period. To estimate the un-
adjusted prevalence ratio of ESA hyporesponsiveness in the
after versus before period, we used Mantel-Haenszel
methods for matched designs35 to analyze the 2×2 table.
To incorporate potential time-varying confounders, we
used an extension of the modified Poisson regression
approach for correlated binary data,36 a valid alternative
when log-binomial regression fails to converge.37,38
The 2 secondary outcomes were hemoglobin level and
ESA dose, each averaged over the 3 months before and
after the increase in CRP level. We used a natural log
transformation of ESA dose due to skewness of the distri-
bution, but we also modeled the untransformed ESA dose.
For these continuous outcomes, we used mixed-effects
linear regression with an indicator variable for after (vs
before) as the exposure contrast of interest. Because mul-
tiple inflammation events per patient could be eligible, we
used a random intercept to account for within-facility and
within-patient clustering.
Factors that are constant within patients (eg, sex), change
uniformly over time (eg, age), or are otherwise constant
within each pre-post pair (eg, DOPPS phase/country) cannot288be confounders in this analysis because they are “matched”
perfectly within patients. Within-patient factors that changed
between the before and after periods (eg, laboratory values
and medications), potentially caused by disease progression,
could plausibly confound the estimated effect of increasing
CRP levels on each outcome. We adjusted for several of these
potential confounders to exclude alternative sources of
changes in hemoglobin level or ESA dose; we included a set of
covariates measured at 2 time points: 4 months before the
high CRP level and 1month before the high CRP level (C1 and
C2, as illustrated in Fig 1). By measuring potential con-
founders before the high CRP level was observed, the cova-
riates cannot be affected by the new inflammation (thus
avoiding controlling for a mediator on the causal pathway),
whereas they may still plausibly affect hemoglobin level and
ESA dose during the before (C1) and after (C2) periods. Our
models thus included adjustment for DOPPS phase, country,
age, sex, vintage (time since HD initiation), bodymass index,
and history of 13 comorbid conditions (listed in Table 1), plus
the following time-dependent variables measured at 4 and 1
month before the observed high CRP level: serum albumin
level, white blood cell count, serum phosphorus level, cina-
calcet use, IV iron dose, hospitalization, and catheter use.
We performed subgroup analyses to assess heteroge-
neity between Japan and the other countries (due to
population differences in CRP levels) and effect modifi-
cation by patient characteristics. We also performed
sensitivity analyses to assess the robustness of our results:
(1) varying the number of CRP measurements during the
3-month before period, (2) restricting to patients’ first
instance of high CRP level, (3) varying the thresholds used
to define “low” and “high” CRP levels, (4) varying the
length of the outcome assessment period, (5) varying theKidney Med Vol 2 | Iss 3 | May/June 2020




No. of eligible instances of high CRP 1,530 2,038
No. of patients 1,293 1,546
Age, y 67.3 (14.5) 68.1 (11.5)
Sex, male 951 (62%) 1438 (71%)




Body mass index, kg/m2
<18 52 (4%) 300 (16%)
18-25 647 (45%) 1,364 (71%)
25-30 492 (34%) 223 (12%)
≥30 249 (17%) 40 (2%)
Comorbid conditions
Coronary artery disease 578 (38%) 664 (33%)
Heart failure 323 (21%) 464 (23%)
Cerebrovascular disease 258 (17%) 313 (15%)
Other cardiovascular disease 500 (33%) 606 (30%)
Cancer (nonskin) 239 (16%) 266 (13%)
Diabetes 574 (38%) 899 (45%)




Lung disease 204 (13%) 62 (3%)
Neurologic disease 200 (13%) 149 (7%)
Psychiatric disorder 289 (19%) 105 (5%)
Peripheral vascular disease 470 (31%) 345 (17%)
Recurrent cellulitis, gangrene 114 (7%) 108 (5%)
Note: Values expressed as mean (standard deviation), median [interquartile
range], or number (percent). Age, time on dialysis, and body mass index were
captured at the time of the CRP level increase (month 0, as defined in Fig 1);
comorbid conditions were captured at DOPPS enrollment. Columns may not
sum to 100% due to rounding.
Abbreviations: A/NZ, Australia/New Zealand; CRP, C-reactive protein;
DOPPS, Dialysis Outcomes and Practice Patterns Study.
Original Researchlongevity of the CRP level increase as sustained
(CRP > 10 mg/L throughout the 3-month after period)
versus transient (CRP ≤ 5 mg/L throughout 3-month after
period), and (6) varying the ESA dose threshold used to
define ESA hyporesponsiveness.
We used multiple imputation, assuming that data were
missing at random, to impute missing covariate values
using the Sequential Regression Multiple Imputation
Method by IVEware.39 Results from 20 such imputed data
sets were combined for the final analysis using Rubin’s
formula.40 The proportion of missing data was <10% for
all covariates in each region, with the exception of white
blood cell count (12%). All analyses were conducted using
SAS software, version 9.4 (SAS Institute).RESULTS
Prevalence of High CRP by Country
As shown in Figure 2, a total of 12,389 patients potentially
eligible for inclusion had a total of 194,917 CRP mea-
surements; the median number of measurements was 13Kidney Med Vol 2 | Iss 3 | May/June 2020(interquartile range [IQR], 6-24). The CRP distribution in
this population is reported by country in Figure 3. The
prevalence of high CRP levels (>10 mg/L) was greatest in
the United Kingdom (43%) and 30% to 40% across other
Europe/ANZ countries; median CRP level was 6 to 8 mg/L
across Europe/ANZ. The prevalence of CRP level >10 mg/
L was much lower in Japan (10%), where 57% of CRP
measurements were ≤1 mg/L.
Self-matched Analysis
Patient Characteristics
After applying the inclusion/exclusion criteria as shown in
Figure 2, we identified 3,568 instances of high CRP levels
(month 0) from 2,839 patients eligible for the primary
analysis: 1,659 from phase 4 DOPPS, 1,316 from phase 5,
and 593 from phase 6. More than half (54%) the eligible
patients were from Japan. Baseline patient characteristics
treated as time-fixed are shown in Table 1 for patients
eligible for the before-after analysis, by region. Compared
with Europe/ANZ, patients in Japan tended to have longer
vintage, have lower body mass index, and were less likely
to have several comorbid conditions.
Time-varying patient characteristics collected longitu-
dinally are shown in Table 2. In the 3 months after versus
before an increase in CRP level, patients in both regions
tended to experience modest decreases in transferrin
saturation and serum albumin level and modest increases
in ferritin level and white blood cell count. The proportion
of patients prescribed IV iron and their respective doses
changed minimally. In Europe/ANZ, patients were more
likely to receive a red blood cell transfusion (6% vs 3%)
or experience inpatient hospitalization (26% vs 19%) in
the 3 months after versus before an increase in CRP
level, but differences were minimal in Japan. More gran-
ular month-level changes in characteristics are shown
in Table S1, in which clear differences are observed
concurrent with the increase in CRP level. Median CRP
level was 19 (IQR, 14-37) in Europe/ANZ and 20 (IQR,
14-36) mg/L in Japan during the reference month,
then decreased to 6 (IQR, 3-14) in Europe/ANZ and 3
(IQR, 1-7) in Japan during the after period, illustrating
that in most cases the increase in CRP level to >10 mg/L
was not sustained.Descriptive Results
In Figure 4, we present unadjusted monthly: (1) mean
hemoglobin levels, (2) mean ESA doses, and (3) pro-
portions of ESA hyporesponsive during the 3 months
before and after the high CRP level was observed (month
0), by region. In the 2 regions, hemoglobin level changes
paralleled each other during the 7-month study period. In
Europe/ANZ, mean hemoglobin level was 11.6 to 11.7 g/
dL in the 3 months before the CRP level increase, decreased
to 11.2 g/dL in month 0 (concurrent with the CRP in-
crease), then rebounded to 11.5 g/dL 3 months later. In
Japan, mean hemoglobin level was w10.8 g/dL in the 3289
Figure 3. C-Reactive protein (CRP) level distribution, by country. Columns may not sum to 100% due to rounding. Abbreviations and
Definitions: A/NZ, Australia/New Zealand; N obs, number of monthly CRP measurements available from these patients (denomina-
tors for the figure); N pats, number of patients with CRP measurements who are potentially eligible for inclusion (as described in Fig
2); UK, United Kingdom.
Original Researchmonths before the CRP level increase, decreased to 10.6 g/
dL in month 0, then rebounded to 10.8 g/dL 3 months
later. Mean ESA dose in Europe/ANZ was about 7,800 U/
wk in the 3 months before the CRP level increase, then
steadily increased to w8,500 U/wk, starting 1 month
following the CRP level increase. In Japan, mean ESA dose
was w5,200 U/wk in the 3 months before the CRP level
increase; in contrast to Europe/ANZ, ESA dose started to
increase in month 0 (immediately following the CRP in-
crease) and increased to >6,000 U/wk 2 months after the
CRP level increase. ESA hyporesponsiveness in both regions
increased in month 0, peaked in month 1, and then started
to decline toward preinflammation levels by month 3.
Model Results
The main findings of this self-matched analysis are
shown in the top row of Table 3. The adjusted preva-
lence ratio of ESA hyporesponsiveness of 1.68 (95% CI,
1.48-1.91) indicates that patients were much more
likely to be hyporesponsive during the 3 months after
versus before the increase in CRP level. The unadjusted
prevalence ratio was also 1.68 (95% CI, 1.48-1.91),
providing strong evidence that our self-matched design
adequately accounted for time-fixed and time-varying
confounders. Results from the adjusted mixed-effects
linear regression models showed that hemoglobin
levels were on average 0.26 g/dL lower (95% CI, 0.22-
0.30) in the 3 months after versus before the increase in
CRP level. The average within-patient change in log(ESA
dose) was 0.080 (95% CI, 0.057-0.104), which, after290exponentiating, can be interpreted as an w8.4% (95%
CI, 5.8%-11.0%) increase in ESA dose. In absolute
terms, the average within-patient increase in ESA dose
was 588 (95% CI, 403-773) U/wk. Table 3 also shows
that results from several subgroup analyses by region,
catheter use, sex, and age were all directionally consis-
tent with the primary analysis.
Table 4 illustrates the robustness of our results to several
sensitivity analyses. Results were consistent when
requiring 3 CRP measurements during the before period
(Table 4[a]) and when restricting to patients’ first instance
of high CRP level (Table 4[b]). Increasing the contrast
when defining low and high CRP levels (eg, from ≤3
to >20 mg/L; Table 4[c]) resulted in a similar decrease in
hemoglobin level but a larger increase in ESA dose
(14.7%). Reducing the length of the after period (eg, from
3 to 1 month) (Table 4[d]) resulted in a larger hemo-
globin level decrease (0.42 g/dL) but smaller ESA dose
increase (4.4%), as also reflected in the descriptive results
(illustrated in Fig 4). We observed much larger changes
among patients for whom the CRP level increase was
sustained at >10 mg/L (0.70 g/dL decrease in hemoglobin
and 14.2% increase in ESA dose) throughout the 3-month
after period, compared with those with a transient CRP
level increase (Table 4[e]). Finally, the adjusted prevalence
ratio for ESA hyporesponsiveness was consistent (1.71 vs
1.68) when increasing the ESA dose thresholds from 6,000
to 7,500 U/wk in Japan and 8,000 to 10,000 U/wk in
Europe/ANZ, and when using the same 8,000-U/wk
threshold in both regions (Table 4[f]).Kidney Med Vol 2 | Iss 3 | May/June 2020
Table 2. Summary Statistics for Time-Varying Patient Characteristics Before and After the CRP Increase From ≤5 to >10 mg/L, by
Region
Europe/ANZ Japan
No. of eligible instances of high CRP 1,530 2,038
No. of patients 1,293 1,546
Time-Varying Characteristic 3 mo “Before” 3 mo “After” 3 mo “Before” 3 mo “After”
CRP, mg/L 3 [2, 4] 6 [3, 14] 2 [1, 3] 3 [1, 7]
TSAT, % 29.6 (12.3) 27.7 (11.9) 25.2 (11.1) 24.1 (11.1)
Serum ferritin, ng/mL 402 [223, 613] 452 [259, 689] 77 [37, 147] 83 [42, 172]
Serum albumin, g/dL 3.8 (0.4) 3.7 (0.5) 3.7 (0.4) 3.6 (0.4)
Serum phosphorus, mg/dL 4.9 (1.4) 4.9 (1.5) 5.2 (1.2) 5.1 (1.2)
Mean WBC count, 103 cells/μL 6.7 (1.9) 6.9 (2.1) 5.9 (1.8) 6.1 (1.9)
IV iron use (any during 3 mo) 1,120 (75%) 1,094 (74%) 622 (31%) 663 (33%)
IV iron dose, mg/mo 261 [145, 435] 272 [145, 435] 116 [58, 174] 116 [58, 174]
Cinacalcet use (any during 3 mo) 270 (18%) 282 (19%) 530 (26%) 538 (27%)
Catheter use (any during 3 mo) 361 (25%) 353 (25%) 11 (1%) 15 (1%)
Transfused (any during 3 mo) 29 (3%) 69 (6%) 27 (2%) 54 (3%)
Hospitalized (any during 3 mo) 280 (19%) 394 (26%) 316 (16%) 346 (17%)
Note: Values expressed as mean (standard deviation), median [interquartile range], or number (percent). Shown among all eligible instances of high CRP level. Monthly
laboratory measures averaged over 3 months. IV iron dose averaged over 3 months among users.
Abbreviations: “after”, 3 months after the C-reactive protein level increase; A/NZ, Australia/New Zealand; “before”, 3 months before the C-reactive protein level
increase; CRP, C-reactive protein; IV, intravenous; TSAT, transferrin saturation; WBC, white blood cell.
Original ResearchDISCUSSION
This self-matched longitudinal (before-after) design and
analysis tracked real-world changes in anemia control and
ESA dosing in an international sample of HD patients
during the 3 months before and after detection of new
inflammation by routine CRP measurement. The results
supported our hypothesis of a hemoglobin level decrease,
concurrent with the increase in CRP level, and ESA dose
increase within 1 month, resulting in greater ESA resis-
tance and exposing patients to the potential risks of larger
ESA doses.7-10 The associations were particularly strong
among patients for whom the CRP level increase was
sustained over the subsequent 3 months, further sup-
porting a causal relation between inflammation and ESA
hyporesponsiveness.
Despite major differences in the study design and ana-
lytic approach, our results were generally consistent with
other longitudinal studies, thus strengthening the evidence
for the link between inflammation and ESA hypores-
ponsiveness.26-28 Bradbury et al26 observed that elevated
CRP levels led to larger ESA doses at the same hemoglobin
levels. However, the authors acknowledged the potential
for selection bias in their US HD sample because only
w1% of patients had CRP measured. These patients were
likely selected for CRP measurement due to suspicion of
inflammation because the median CRP level (20 mg/L)
was much higher than reported in other HD
populations.17,24,25
Gillespie et al27 conducted a case-crossover study of ESA
hyporesponsiveness defined as hemoglobin level < 10 g/
dL and ESA dose greater than the median dose of 80 U/kg
per week, which they observed in 672 European HD pa-
tients. Among the many exposures that Gillespie et al27Kidney Med Vol 2 | Iss 3 | May/June 2020examined, they found a positive association with CRP
level (adjusted odds ratio for highest vs lowest quartile [no
values provided], 2.02; 95% CI, 1.20-3.38).
Kimachi et al28 used Japanese DOPPS data from phases 2
to 4 (2002-2011) to evaluate the cumulative incidence of
ESA hyporesponsiveness (hemoglobin < 10 g/dL
and >9,000 U/wk of ESA) by baseline CRP. Those authors
found that the risk for ESA hyporesponsiveness was highest
at CRP levels > 10 mg/L but also elevated at CRP levels of 3
to 10 mg/L (vs CRP < 1 mg/L).
The proportion of CRP measurements > 10 mg/L was
much lower in Japan (10%) than in Europe/ANZ (34%),
consistent with prior research. 17,24,28 Japanese HD prac-
tices may help explain this discrepancy, including the use
of ultrapure dialysate fluid to keep endotoxins low and
avoidance of central venous catheters, which can cause
infections and inflammatory reactions.31 However, CRP
levels are also lower in Asians than in whites outside the
HD setting,41 suggesting dietary, environmental, and/or
genetic factors as likely contributors to differences in CRP
levels.15
In our analysis, hemoglobin levels began to decline in
the same month that CRP levels increased. Elevated CRP
level is generally considered a marker of inflammation, so
new inflammation may alter hemoglobin levels roughly
concurrent with its effect on CRP levels. In Japan the in-
crease in ESA dose occurs in the same month that hemo-
globin levels began to decline (ie, month 0), but in
Europe/ANZ, the initial ESA dose increase lags by 1
month. Increases in CRP levels from ≤5 to >10 mg/L were
also less likely to be sustained for 3-plus months in Japan
(5%) than in Europe/ANZ (18%). These findings suggest
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Figure 4. (A) Mean monthly hemoglobin level, (B) mean monthly erythropoiesis-stimulating agent (ESA) dose, and (C) percent ESA
hyporesponsive in the 3 months before and after a C-reactive protein (CRP) level increase from ≤5 to >10 mg/L, by region. Mean
hemoglobin level and ESA dose were calculated as the average across all patients at each time point. Months during which ESA was
not prescribed are considered 0 U/wk. ESA hyporesponsive defined as hemoglobin level <10 g/dL and ESA dose > 6,000 (Japan)
or >8,000 (Europe/ANZ) U/wk. Abbreviations: ANZ, Australia/New Zealand; CI, confidence interval.
Original Researchdecline in hemoglobin levels than in Europe/ANZ or that
Japanese providers are reacting proactively to increases in
CRP levels below the 10-mg/L threshold used in this
analysis.
CRP is relatively inexpensive and convenient to
routinely measure in the HD setting42; this is generallyTable 3. Within-Patient Changes (95% CI) in Hemoglobin, ESA D
Versus After the CRP Increase From ≤5 to >10 mg/L, Overall and
Subgroup
Instances of
High CRP Change in Hb, g/dL
Overall 3,568 −0.26 (−0.30 to −0.22)
By region
Europe/ANZ 1,530 −0.34 (−0.41 to −0.27)
Japan 2,038 −0.20 (−0.25 to −0.16)
By catheter use during “before” period
Any catheter use 372 −0.50 (−0.62 to −0.37)
No catheter use 2,908 −0.23 (−0.27 to −0.19)
By sex
Male 2,389 −0.25 (−0.30 to −0.20)
Female 1,177 −0.29 (−0.36 to −0.22)
By age, y
<60 874 −0.23 (−0.31 to −0.15)
60-75 1,559 −0.27 (−0.33 to −0.21)
>75 1,135 −0.28 (−0.35 to −0.21)
Note: Linear mixed model with random facility and patient intercepts to calculate
calculate prevalence ratio of ESA hyporesponsiveness. Baseline adjustment for D
conditions and adjustment for serum albumin level, white blood cell count, serum pho
use at 4 and 1 month before the CRP level increase. ESA hyporesponsiveness defin
U/wk. Primary analysis includes patients with CRP levels ≤ 5 mg/L during the 3-mon
“after” period.
Abbreviations: ANZ, Australia/New Zealand; CI, confidence interval; CRP, C-rea
erythropoiesis-stimulating agent; Hb, hemoglobin.
292done in Europe and Japan, but not in North America.
Routine measurement of CRP can potentially help better
identify causes of and inform targeted strategies to
reduce inflammation in HD patients. For example, an
increase in CRP level may prompt examination for the




Prevalence Ratio of ESA
Hyporesponsiveness
8.4% (5.8% to 11.0%) 1.68 (1.48 to 1.91)
5.2% (1.5% to 9.0%) 2.09 (1.60 to 2.74)
10.8% (7.4% to 14.3%) 1.54 (1.34 to 1.78)
9.8% (2.0% to 18.3%) 3.16 (1.74 to 5.76)
8.0% (5.4% to 10.8%) 1.54 (1.35 to 1.77)
7.2% (4.1% to 10.4%) 1.63 (1.40 to 1.90)
10.8% (6.3% to 15.4%) 1.81 (1.45 to 2.27)
9.2% (4.1% to 14.4%) 1.51 (1.14 to 1.98)
7.8% (3.9% to 11.8%) 1.79 (1.47 to 2.17)
8.9% (4.7% to 13.3%) 1.66 (1.35 to 2.04)
mean changes in Hb level and ESA dose, and modified Poisson regression to
OPPS phase, country, age, sex, vintage, body mass index, and 13 comorbid
sphorus level, cinacalcet use, intravenous iron dose, hospitalization, and catheter
ed as Hb level <10 g/dL and ESA dose >6,000 (Japan) or >8,000 (Europe/ANZ)
th “before” period, increased to >10 mg/L, then followed up during the 3-month
ctive protein; DOPPS, Dialysis Outcomes and Practice Patterns Study; ESA,
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Table 4. Within-Patient Changes (95% CI) in Hemoglobin, ESA Dose, and ESA Hyporesponsiveness From the 3 Months Before










Primary analysis 3,568 −0.26 (−0.30 to −0.22) 8.4% (5.8% to 11.0%) 1.68 (1.48 to 1.91)
(a) CRP measurements during 3-mo “before” period
CRP measured all 3 mo 2,312 −0.26 (−0.30 to −0.21) 9.9% (6.7% to 13.1%) 1.65 (1.42 to 1.93)
CRP measured in 1 or 2 of the 3 mo 1,256 −0.28 (−0.36 to −0.21) 5.9% (1.8% to 10.2%) 1.76 (1.41 to 2.20)
(b) Restricting to 1 record per patient
First instance of high CRP during
DOPPS enrollment
2,839 −0.27 (−0.31 to −0.22) 8.1% (5.5% to 10.8%) 1.74 (1.50 to 2.01)
(c) Varying thresholds for “low” and “high” CRP
CRP increase from ≤10 to >20 mg/L 3,008 −0.27 (−0.32 to −0.23) 10.2% (7.4% to 13.1%) 1.56 (1.35 to 1.80)
CRP increase from ≤5 to >20 mg/L 1,703 −0.30 (−0.36 to −0.24) 11.7% (8.0% to 15.6%) 1.70 (1.39 to 2.07)
CRP increase from ≤3 to >20 mg/L 1,053 −0.27 (−0.34 to −0.19) 14.7% (9.7% to 19.8%) 1.66 (1.29 to 2.15)
CRP increase from ≤3 to >10 mg/L 2,178 −0.27 (−0.32 to −0.22) 11.1% (7.8% to 14.5%) 1.73 (1.46 to 2.05)
CRP increase from ≤3 to >5 mg/L 4,230 −0.18 (−0.22 to −0.15) 6.4% (4.2% to 8.7%) 1.43 (1.25 to 1.63)
CRP increase from ≤1 to >5 mg/L 1,624 −0.18 (−0.23 to −0.12) 10.9% (7.2% to 14.7%) 1.36 (1.10 to 1.68)
(d) Vary length of “after” period for assessing outcome
1-mo “after” period 3,958 −0.42 (−0.46 to −0.37) 4.4% (1.9% to 6.9%) 1.91 (1.68 to 2.17)
2-mo “after” period 3,755 −0.34 (−0.39 to −0.30) 7.7% (5.3% to 10.2%) 1.82 (1.60 to 2.08)
(e) By longevity of CRP increase in “after” period
Sustained: CRP > 10 mg/L in “after”
period
352 −0.70 (−0.85 to −0.55) 14.2% (4.7% to 24.5%) 2.89 (1.97 to 4.24)
Transient: CRP ≤ 5 mg/L in “after”
period
1,652 −0.14 (−0.19 to −0.09) 5.6% (2.1% to 9.1%) 1.22 (1.00 to 1.48)
(f) Vary thresholds for ESA hyporesponsiveness
ESA dose >8,000 (Japan) or >8,000
(Europe/ANZ) U/wk
3,568 NA NA 1.74 (1.51 to 2.00)
ESA dose >7,500 (Japan) or >10,000
(Europe/ANZ) U/wk
3,568 NA NA 1.71 (1.49 to 1.96)
Note: Linear mixed model with random facility and patient intercepts to calculate mean changes in Hb level and ESA dose, and modified Poisson regression to
calculate prevalence ratio of ESA hyporesponsiveness. Baseline adjustment for DOPPS phase, country, age, sex, vintage, body mass index, and 13 comorbid
conditions and adjustment for serum albumin level, white blood cell count, serum phosphorus level, cinacalcet use, intravenous iron dose, hospitalization, and catheter
use at 4 and 1 month before the CRP increase. ESA hyporesponsiveness defined as Hb level < 10 g/dL and ESA dose > 6,000 (Japan) or >8,000 (Europe/ANZ) U/
wk unless otherwise specified. Primary analysis includes patients with CRP levels ≤ 5 mg/L during the 3-month “before” period, increased to >10 mg/L, then followed
up during the 3-month “after” period. Relative change in ESA dose based on models using log(ESA dose) as outcome.
Abbreviations: ANZ, Australia/New Zealand; CI, confidence interval; CRP, C-reactive protein; DOPPS, Dialysis Outcomes and Practice Patterns Study; ESA,
erythropoiesis-stimulating agent; Hb, hemoglobin; NA, not applicable.
Original Researchexaminations) and timely initiation of antimicrobial
therapy when indicated. Other longer-term strategies to
limit or reduce inflammation include removing old
nonfunctioning arteriovenous grafts,43,44 transplant ne-
phrectomy,45 using ultrapure dialysate fluid,13,15 and
improving diet and exercise.18 Specific to anemic pa-
tients, quicker recognition of new inflammation can
help identify the cause of worsening anemia and guide
reactive ESA and IV iron dosing decisions. Further,
frequent assessment of inflammation can help identify
patients who may be candidates for new alternative
anemia therapies, such as hypoxia-inducible factor prolyl
hydroxylase inhibitors, not yet approved in the United
States or Europe, that may be less susceptible to the
effects of inflammation than current ESA and IV iron-
based treatment regimens.46-48
This study had some limitations. First, CRP levels can be
highly variable over time within a patient,49,50 likely due
to infections causing acute increases. The resulting error inKidney Med Vol 2 | Iss 3 | May/June 2020classifying CRP level is likely to be nondifferential with
respect to the outcomes and covariates, thus probably
resulting in bias toward the null (ie, underestimates).
Further, subgroup analyses show that associations were
stronger when CRP level increases were sustained over the
3-month after period.
Second, although the study would be strengthened by
potentially better markers of inflammation such as inter-
leukin 6, increasing CRP level was the best indicator of
inflammation available through routine measurement.
Third, if patients excluded due to fewer than 3 months
of data postinflammation were more likely to have expe-
rienced ESA hyporesponsiveness following their high CRP
levels, the true effect may be underestimated. However,
that bias is likely minimal because of the small proportion
(14%) of excluded patients.
Fourth, although we adjusted for several time-varying
confounders, it is possible that our estimates experienced
residual confounding by unmeasured time-varying risk293
Original Researchfactors for ESA hyporesponsiveness. However, because the
extensive covariate adjustments in our models had little
impact on our estimates in this self-matched study, the
likelihood of bias due to unmeasured confounding is low.
Several strengths distinguish this analysis from other lon-
gitudinal studies of inflammation and ESA hyporesponsive-
ness.26-28 First, the longitudinal study design focuses on
incident inflammation to avoid the temporal ambiguity of
cross-sectional designs. By matching patients to themselves
and measuring outcomes before and after the detection of
elevated CRP levels, this design does not require a comparison
group of patients who did not experience an increase in CRP
level. The self-matching seems to have controlled adequately
for potential confounders, both fixed and time-varying fac-
tors, as evidenced by the unchanged estimates after additional
adjustment. It is thus likely that residual bias by additional
unmeasured time-varying confounders would be minimal.
However, future studies could perform between-patient
comparisons that we did not investigate.
Second,weused a large international sample ofHDpatients
from facilities that routinely measured CRP, the best available
marker of inflammation, to avoid bias in which a clinical
indication for measuring CRP also affects the outcome (a
phenomenon we call “measurement-by-indication bias”).
Third, in addition to a single ESA hyporesponse
outcome, we treated the 2 components of that outcome,
hemoglobin level and ESA dose, as separate continuous
outcomes, allowing us to better explore relative changes in
ESA sensitivity without relying on the flawed erythropoi-
etin resistance index.51,52
This study demonstrates that new inflammation, as
detected by an increase in CRP level, is associated with the
development of ESA resistance and reduction in hemoglobin
levels under current anemia treatment paradigms. These
findings speak to a potentially important role for anemia
therapies that are less susceptible to the effects of
inflammation.SUPPLEMENTARY MATERIAL
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Table S1: Monthly summary statistics for time-varying patient char-
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